NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 230 filers reported holding NEKTAR THERAPEUTICS in Q2 2022. The put-call ratio across all filers is 0.20 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,346,426 | +2822.1% | 3,939,600 | +2722.1% | 0.33% | +2658.3% |
| Q2 2023 | $80,298 | -18.2% | 139,600 | 0.0% | 0.01% | -20.0% |
| Q1 2023 | $98,125 | -73.6% | 139,600 | -15.0% | 0.02% | -72.2% |
| Q4 2022 | $371,069 | -73.0% | 164,190 | -61.8% | 0.05% | -68.0% |
| Q3 2022 | $1,376,000 | -15.8% | 430,037 | 0.0% | 0.17% | -31.9% |
| Q2 2022 | $1,634,000 | -29.5% | 430,037 | 0.0% | 0.25% | -46.6% |
| Q1 2022 | $2,318,000 | -37.4% | 430,037 | +65.4% | 0.46% | -71.9% |
| Q2 2016 | $3,700,000 | +3.5% | 260,000 | 0.0% | 1.65% | +1.3% |
| Q1 2016 | $3,575,000 | -66.0% | 260,000 | -71.5% | 1.63% | -60.7% |
| Q2 2013 | $10,523,000 | – | 911,053 | – | 4.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |